Daniel Markwardt1, Lesca Holdt2, Christian Steib1, Andreas Benesic1, Flemming Bendtsen3, Mauro Bernardi4, Richard Moreau5, Daniel Teupser2, Julia Wendon6, Frederik Nevens7, Jonel Trebicka8,9, Elisabet Garcia10, Marco Pavesi10, Vicente Arroyo9, Alexander L Gerbes1. 1. Liver Centre Munich, Department of Medicine II, Hospital of the University of Munich, Munich, Germany. 2. Institute of Laboratory Medicine, Hospital of the University of Munich, Munich, Germany. 3. Gastro Unit, Medical Division, Hvidovre University Hospital, Hvidovre, Denmark. 4. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. 5. DHU Unity, Service d'Hépatologie, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Clichy; Centre de Recherche sur l'Inflammation CRI, INSERM, CNRS, Université Paris Diderot; and Laboratoire d'Excellence (Labex) Inflammex, COMUE Sorbonne Paris Cité, Paris, France. 6. King's College Hospital, London, UK. 7. Department of Hepatology, University Hospitals KU Leuven, Leuven, Belgium. 8. Department of Internal Medicine I, University Hospital of Bonn, Bonn, Germany. 9. European Foundation for the Study of Chronic Liver Failure, European Foundation for the Study of Chronic Liver Failure, Barcelona, Spain. 10. Data Management Centre, European Foundation for the Study of Chronic Liver Failure, Barcelona, Spain.
Abstract
The development of acute-on-chronic liver failure (ACLF) in patients with liver cirrhosis is associated with high mortality rates. Renal failure is the most significant organ dysfunction that occurs in ACLF. So far there are no biomarkers predicting ACLF. We investigated whether cystatin C (CysC) and neutrophil gelatinase-associated lipocalin (NGAL) can predict development of renal dysfunction (RD), hepatorenal syndrome (HRS), ACLF, and mortality. We determined the plasma levels of CysC and NGAL in 429 patients hospitalized for acute decompensation of cirrhosis in the EASL-CLIF Acute-on-Chronic Liver Failure in Cirrhosis (CANONIC) study. The patients were followed for 90 days. Patients without RD or ACLF at inclusion but with development of either had significantly higher baseline concentrations of CysC and NGAL compared to patients without. CysC, but not NGAL, was found to be predictive of RD (odds ratio, 9.4; 95% confidence interval [CI], 1.8-49.7), HRS (odds ratio, 4.2; 95% CI, 1.2-14.8), and ACLF (odds ratio, 5.9; 95% CI, 1.3-25.9). CysC at day 3 was not found to be a better predictor than baseline CysC. CysC and NGAL were both predictive of 90-day mortality, with hazard ratios for CysC of 3.1 (95% CI, 2.1-4.7) and for NGAL of 1.9 (95% CI, 1.5-2.4). CONCLUSION: Baseline CysC is a biomarker of RD, HRS, and ACLF and an independent predictor of mortality in patients with acutely decompensated liver cirrhosis, though determining CysC at day 3 did not provide any benefit; while NGAL is also associated with short-term mortality, it fails to predict development of RD, HRS, and ACLF. Baseline CysC may help to identify patients at risk earlier and improve clinical management. (Hepatology 2017;66:1232-1241).
The development of acute-on-chronic liver failure (ACLF) in patients with liver cirrhosis is associated with high mortality rates. Renal failure is the most significant organ dysfunction that occurs in ACLF. So far there are no biomarkers predicting ACLF. We investigated whether cystatin C (CysC) and neutrophil gelatinase-associated lipocalin (NGAL) can predict development of renal dysfunction (RD), hepatorenal syndrome (HRS), ACLF, and mortality. We determined the plasma levels of CysC and NGAL in 429 patients hospitalized for acute decompensation of cirrhosis in the EASL-CLIF Acute-on-Chronic Liver Failure in Cirrhosis (CANONIC) study. The patients were followed for 90 days. Patients without RD or ACLF at inclusion but with development of either had significantly higher baseline concentrations of CysC and NGAL compared to patients without. CysC, but not NGAL, was found to be predictive of RD (odds ratio, 9.4; 95% confidence interval [CI], 1.8-49.7), HRS (odds ratio, 4.2; 95% CI, 1.2-14.8), and ACLF (odds ratio, 5.9; 95% CI, 1.3-25.9). CysC at day 3 was not found to be a better predictor than baseline CysC. CysC and NGAL were both predictive of 90-day mortality, with hazard ratios for CysC of 3.1 (95% CI, 2.1-4.7) and for NGAL of 1.9 (95% CI, 1.5-2.4). CONCLUSION: Baseline CysC is a biomarker of RD, HRS, and ACLF and an independent predictor of mortality in patients with acutely decompensated liver cirrhosis, though determining CysC at day 3 did not provide any benefit; while NGAL is also associated with short-term mortality, it fails to predict development of RD, HRS, and ACLF. Baseline CysC may help to identify patients at risk earlier and improve clinical management. (Hepatology 2017;66:1232-1241).
Authors: Kavish R Patidar; Pranav S Garimella; Etienne Macedo; James E Slaven; Marwan S Ghabril; Regina E Weber; Melissa Anderson; Eric S Orman; Lauren D Nephew; Archita P Desai; Naga P Chalasani; Tarek M El-Achkar Journal: Am J Physiol Gastrointest Liver Physiol Date: 2019-08-14 Impact factor: 4.052
Authors: Ayse L Mindikoglu; Antone R Opekun; William E Mitch; Laurence S Magder; Robert H Christenson; Thomas C Dowling; Matthew R Weir; Stephen L Seliger; Charles D Howell; Jean-Pierre Raufman; Abbas Rana; John A Goss; Saira A Khaderi; John M Vierling Journal: Dig Dis Sci Date: 2018-02-01 Impact factor: 3.199
Authors: Kenneth L Hastings; Martin D Green; Bin Gao; Patricia E Ganey; Robert A Roth; Gary R Burleson Journal: Int J Toxicol Date: 2020 Mar/Apr Impact factor: 2.032
Authors: Ezequiel Mauro; Juan Manuel Diaz; Lucrecia Garcia-Olveira; Juan Carlos Spina; Lorena Savluk; Fernanda Zalazar; Julia Saidman; Martin De Santibañes; Juan Pekolj; Eduardo De Santibañes; Gonzalo Crespo; Juan G Abraldes; Adrían Gadano Journal: Hepatol Commun Date: 2022-03-03